Breast Cancer: Genevieve's Survivor Story
This breast cancer diagnosis at a glance
- Biomarkers
- 1987 tumor not hormone-receptive; 2017 tumor hormone-receptive. 2022 full marker panel not stated.
- Sex
- Female
- Treatment
- surgery, radiation, chemotherapy, hormone therapy, targeted therapy and reconstruction
- Outcome
- Cancer-Free / NED
Treatment course, step by step
- 1987 biopsy and lumpectomy removed breast cancer and lymph nodes
- Radiation and monthly chemotherapy followed
- Remission was declared after 5 years
- 2017 right mastectomy with dorsal-flap reconstruction treated a new hormone-sensitive tumor
- Letrozole and later reconstruction refinements followed
- 2022 nodules were removed or biopsied and confirmed cancer
- Surgery and port placement were done at the end of March 2022
- Weekly Taxol ran for about 4 months and stopped after 15 doses because of neuropathy
- Perjeta plus Herceptin continued every 3 weeks, later switching to Phesgo injections on October 31, 2022
- Hormone blockers included letrozole and then anastrozole
- PET scans every 3 to 4 months were clear.
What happened, in summary
Genevieve first found breast cancer in 1987, at age 40, after noticing a small hard lump in her right breast. Surgery removed the tumor and lymph nodes while preserving the breast, and pathology showed an aggressive non-hormone-receptive cancer. She received radiation, then monthly chemotherapy, and after 5 years was declared in remission. She stayed in remission for 30 years. In 2017, routine imaging in France found a new tumor in the same breast. This time she needed the entire right breast removed and chose dorsal-flap reconstruction. The tumor was hormone-receptive, so she started letrozole and later had reconstruction refinements, including nipple tattooing and reduction of the left breast. In late 2021, she became worried about hard nodules in the reconstructed breast. A biopsy confirmed cancer, and surgery took place at the end of March 2022. A port was placed, and she received weekly Taxol for about 4 months, stopping after 15 doses because of chemotherapy-induced peripheral neuropathy. She also received Perjeta and Herceptin, then switched to Phesgo injections from October 2022 onward. She continued hormone-blocking therapy, including letrozole and later anastrozole. As of May 2025, PET scans every 3-4 months had remained clear, and she described herself as in remission again.
Where this story comes from
This is a lay summary of an account first published by breastcancer.org. Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer